New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
10:00 EDTESV, SNY, RDS.A, ITG, EVR, ADBE, BSX, CVS, SPW, RJF, GFIG, DVA, TER, WBMD, R, MRO, HST, OFCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Adobe (ADBE) upgraded to Outperform from Underperform at JMP Securities... Corporate Office Properties (OFC) upgraded to Neutral from Sell at Citigroup... DaVita (DVA) upgraded to Buy from Neutral at Nomura... Evercore Partners (EVR) upgraded to Outperform from Market Perform at Keefe Bruyette... GFI Group (GFIG) upgraded to Outperform from Market Perform at Keefe Bruyette... Host Hotels (HST) upgraded to Buy from Neutral at Citigroup... ITG (ITG) upgraded to Outperform from Market Perform at Keefe Bruyette... Marathon Oil (MRO) upgraded to Buy from Neutral at Goldman... Raymond James (RJF) upgraded to Outperform from Market Perform at Keefe Bruyette... Royal Dutch Shell (RDS.A) upgraded to Outperform from Neutral at Credit Suisse... Ryder (R) upgraded to Top Pick from Outperform at RBC Capital... SPX Corp. (SPW) upgraded to Buy from Neutral at Nomura... Sanofi (SNY) upgraded to Buy from Hold at Jefferies... WebMD (WBMD) upgraded to Market Perform from Underperform at Raymond James... CVS Caremark (CVS) upgraded to Outperform from Neutral at Macquarie... Ensco (ESV) upgraded to Buy from Hold at Jefferies... Teradyne (TER) upgraded to Outperform from Sector Perform at Pacific Crest... Boston Scientific (BSX) upgraded to Overweight from Underweight at Barclays.
News For A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 23, 2015
09:21 EDTCVSConsolidated Tomoka disposes non-core income property for about $5.4M
Subscribe for More Information
November 20, 2015
06:09 EDTSNYSanofi, AstraZeneca to exchange more than 210,000 compounds
Subscribe for More Information
November 19, 2015
16:43 EDTBSXBoston Scientific receives CE Mark for next generation WATCHMAN FLX
Boston Scientific announced that the first implants of the WATCHMAN FLX Left Atrial Appendage Closure, or LAAC, Device - the latest generation of the WATCHMAN Device - occurred in Europe following CE mark approval.
16:10 EDTAAgilent increases cash dividend to 11.5c per share
Subscribe for More Information
10:42 EDTBSXLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
November 18, 2015
15:40 EDTCVSCongressman says U.S. may need look at pharmacy competition, dealReporter says
Subscribe for More Information
11:01 EDTCVSTarget says working with CVS team to secure regulatory approval for deal
Target (TGT) says "pleased" with progress to date of CVS (CVS) deal.
08:11 EDTSNYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
November 17, 2015
10:17 EDTCVSHouse Judiciary Committee to hold a hearing
The Subcommittee on Regulatory Reform, Commercial and Antitrust Law holds a hearing entitled, "The State of Competition in the Pharmacy Benefit Manager and Pharmacy Marketplaces" with Vice President Bricker of Express Scripts and Senior Vice President Pons of CVS Health on November 17 at 3 pm. Webcast Link
08:43 EDTAAgilent pullback after earnings a buying opportunity, says Cowen
Cowen said any pullback in Agilent after its Q4 earnings report would be a buying opportunity. Even though guidance was lower than expected, the firm still thinks 2017 targets are achievable. Cowen maintained its Market Perform rating and $39 price target on Agilent shares.
November 16, 2015
18:26 EDTAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Nuance (NUAN), up 9.5%. ALSO HIGHER: Ocera Therapeutics (OCRX), up 26.6% after announcing Phase 1 study results for the company's oral formulation of OCR-002. DOWN AFTER EARNINGS: Urban Outfitters (URBN), down 11.5%... Agilent (A), down 1.3%. ALSO LOWER: Wayfair (W), down 2% after Bloomberg reported that Whitney Tilson said that Wayfair is currently his largest short.
16:10 EDTAAgilent reports Q4 LSAG revenue down 4% to $515M
Subscribe for More Information
16:09 EDTAAgilent sees FY16 adjusted EPS $1.85-$1.91, consensus $1.97
Sees FY16 revenue $4.15B-$4.17B, consensus $4.21B.
16:08 EDTAAgilent sees Q1 adjusted EPS 42c-44c, consensus 47c
Subscribe for More Information
16:07 EDTAAgilent reports Q4 adjusted EPS 50c, consensus 47c
Subscribe for More Information
15:02 EDTANotable companies reporting after market close
Subscribe for More Information
09:33 EDTESVEnsco announces retirement of CFO Jay Swent
Subscribe for More Information
09:06 EDTCVSDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
06:18 EDTCVSDiplomat Pharmacy selloff brings 'compelling' entry point, says Leerink
Subscribe for More Information
November 13, 2015
08:01 EDTBSXConsultant says coverage decision positive for Boston Scientific, says Stifel
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use